BACKGROUND: Gentamicin has been used for the treatment of gonorrhea in Malawi since 1993. However, declining clinical cure rates have been suspected. We evaluated current Neisseria gonorrhoeae susceptibility to gentamicin in vitro and clinically. METHODS: Men with acute urethritis were recruited at the Bwaila District Hospital STI Clinic in Lilongwe, Malawi, between January 2017 and August 2019. All men provided urethral swabs for etiological testing at enrollment and test of cure (TOC), 1 week later, using Gram-stained microscopy and culture. We used Etest to determine minimum inhibitory concentrations (MICs) of gentamicin, azithromycin, cefixime, ceftriaxone, ciprofloxacin, and spectinomycin; disc diffusion for tetracycline susceptibility; and whole-genome sequencing (WGS) to verify/refute treatment failure. RESULTS: Among 183 N. gonorrhoeae culture-positive men enrolled, 151 (82.5%) had a swab taken for TOC. Of these 151 men, 16 (10.6%) had a positive culture at TOC. One hundred forty-one baseline isolates were tested for gentamicin susceptibility using Etest: 2 (1.4%), MIC = 2 μg/mL; 111 (78.7%), MIC = 4 μg/mL; and 28 (19.9%), MIC = 8 μg/mL. All isolates were susceptible to azithromycin, cefixime, ceftriaxone, and spectinomycin, whereas 63.1% had intermediate susceptibility or resistance to ciprofloxacin. Almost all (96.1%) isolates were resistant to tetracycline. All examined isolates cultured at TOC (n = 13) had gentamicin MICs ≤8 μg/mL. Ten men had pretreatment and posttreatment isolates examined by whole-genome sequencing; 2 (20%) were verified new infections (4119 and 1272 single-nucleotide polymorphisms), whereas 8 (80%) were confirmed treatment failures (0-1 single-nucleotide polymorphism). CONCLUSIONS: Gentamicin MICs poorly predict gonorrhea treatment outcome with gentamicin, and treatment failures are verified with gonococcal strains with in vitro susceptibility to gentamicin. The first-line treatment of gonorrhea in Malawi should be reassessed.
BACKGROUND: Gentamicin has been used for the treatment of gonorrhea in Malawi since 1993. However, declining clinical cure rates have been suspected. We evaluated current Neisseria gonorrhoeae susceptibility to gentamicin in vitro and clinically. METHODS: Men with acute urethritis were recruited at the Bwaila District Hospital STI Clinic in Lilongwe, Malawi, between January 2017 and August 2019. All men provided urethral swabs for etiological testing at enrollment and test of cure (TOC), 1 week later, using Gram-stained microscopy and culture. We used Etest to determine minimum inhibitory concentrations (MICs) of gentamicin, azithromycin, cefixime, ceftriaxone, ciprofloxacin, and spectinomycin; disc diffusion for tetracycline susceptibility; and whole-genome sequencing (WGS) to verify/refute treatment failure. RESULTS: Among 183 N. gonorrhoeae culture-positive men enrolled, 151 (82.5%) had a swab taken for TOC. Of these 151 men, 16 (10.6%) had a positive culture at TOC. One hundred forty-one baseline isolates were tested for gentamicin susceptibility using Etest: 2 (1.4%), MIC = 2 μg/mL; 111 (78.7%), MIC = 4 μg/mL; and 28 (19.9%), MIC = 8 μg/mL. All isolates were susceptible to azithromycin, cefixime, ceftriaxone, and spectinomycin, whereas 63.1% had intermediate susceptibility or resistance to ciprofloxacin. Almost all (96.1%) isolates were resistant to tetracycline. All examined isolates cultured at TOC (n = 13) had gentamicin MICs ≤8 μg/mL. Ten men had pretreatment and posttreatment isolates examined by whole-genome sequencing; 2 (20%) were verified new infections (4119 and 1272 single-nucleotide polymorphisms), whereas 8 (80%) were confirmed treatment failures (0-1 single-nucleotide polymorphism). CONCLUSIONS: Gentamicin MICs poorly predict gonorrhea treatment outcome with gentamicin, and treatment failures are verified with gonococcal strains with in vitro susceptibility to gentamicin. The first-line treatment of gonorrhea in Malawi should be reassessed.
Authors: Magnus Unemo; Monica M Lahra; Michelle Cole; Patricia Galarza; Francis Ndowa; Irene Martin; Jo-Anne R Dillon; Pilar Ramon-Pardo; Gail Bolan; Teodora Wi Journal: Sex Health Date: 2019-09 Impact factor: 2.706
Authors: Lillian B Brown; Robert Krysiak; Gift Kamanga; Clemente Mapanje; Happiness Kanyamula; Blessings Banda; Chisale Mhango; Mariah Hoffman; Debbie Kamwendo; Marcia Hobbs; Mina C Hosseinipour; Francis Martinson; Myron S Cohen; Irving F Hoffman Journal: Sex Transm Dis Date: 2010-03 Impact factor: 2.830
Authors: Michelle J Cole; Wei Tan; Helen Fifer; Clare Brittain; Lelia Duley; Trish Hepburn; Tessa Lawrence; Alan A Montgomery; Kirsty Sprange; Sukhwinder Thandi; Colin Churchward; Francesco Tripodo; Neil Woodford; Jonathan D C Ross Journal: J Antimicrob Chemother Date: 2020-02-01 Impact factor: 5.790
Authors: Teodora Wi; Monica M Lahra; Francis Ndowa; Manju Bala; Jo-Anne R Dillon; Pilar Ramon-Pardo; Sergey R Eremin; Gail Bolan; Magnus Unemo Journal: PLoS Med Date: 2017-07-07 Impact factor: 11.069
Authors: Sancta St Cyr; Lindley Barbee; Kimberly A Workowski; Laura H Bachmann; Cau Pham; Karen Schlanger; Elizabeth Torrone; Hillard Weinstock; Ellen N Kersh; Phoebe Thorpe Journal: MMWR Morb Mortal Wkly Rep Date: 2020-12-18 Impact factor: 17.586
Authors: Jane Rowley; Stephen Vander Hoorn; Eline Korenromp; Nicola Low; Magnus Unemo; Laith J Abu-Raddad; R Matthew Chico; Alex Smolak; Lori Newman; Sami Gottlieb; Soe Soe Thwin; Nathalie Broutet; Melanie M Taylor Journal: Bull World Health Organ Date: 2019-06-06 Impact factor: 9.408
Authors: Mitch Matoga; Jane S Chen; Robert Krysiak; Beatrice Ndalama; Cecilia Massa; Naomi Bonongwe; Esther Mathiya; Blessing Kamtambe; Edward Jere; Tarsizio Chikaonda; Daniel Golparian; Magnus Unemo; Myron S Cohen; Marcia M Hobbs; Irving F Hoffman Journal: Sex Transm Dis Date: 2022-04-01 Impact factor: 2.830
Authors: Concerta L Holley; Vijaya Dhulipala; Jacqueline T Balthazar; Adriana Le Van; Afrin A Begum; Shao-Chun Chen; Timothy D Read; Mitch Matoga; Irving F Hoffman; Daniel Golparian; Magnus Unemo; Ann E Jerse; William M Shafer Journal: Antimicrob Agents Chemother Date: 2022-04-25 Impact factor: 5.938